Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...
Creative Biolabs is helping researchers overcome challenges of gene therapy research by providing analytical testing ...
Key market opportunities include the rising prevalence of chronic diseases and increased regulatory approvals driving demand ...
Based on Ajinomoto Group’s collaborative development with Forge Biologics, now available worldwide Incheon, Korea — December 2025 — Ajinomoto CELLiST Korea, a subsidiary of the Ajinomoto Group ...
A new study characterizes a bioengineered adeno-associated virus (AAV)3B capsid variant that demonstrates improved transduction to human liver cells. Another advantage of the AAV3B-V04 capsid was its ...
The "Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of Administration, Scale of Operation and ...
The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results